

NextPharma Board member Prof Trevor Jones CBE elected to the French Academie nationale de Pharmacie

London 13 January, 2006 - NextPharma is delighted to announce that Prof. Trevor Jones CBE who has been on the Board of NextPharma since December 2004 has been elected to the French Academie nationale de Pharmacie at a ceremony held in the ancient Salle des Actes at the University of Paris on 4th January, 2006. Also elected at the same ceremony was Jean-François Dehecq – Chairman and CEO of sanofi aventis.

In his oration, the outgoing President of the Academie, Prof Jean-Pierre Lousson, cited the contribution that Prof. Trevor Jones had made to international pharmaceutical science during his career and his long association with scientists in France. During his time at the Boots Company he was responsible for the technical transfer of Brufen formulations to Labs Dacour in Paris including the development of a suppository formulation. As R&D Director at Wellcome plc he had responsibility for the R&D activities of Wellcome France in Sophie Antipolis and in Paris. During that time his team at Wellcome co-developed the anticancer drug Navelbine with Pierre Fabre. For 13 years he was President of the international jury of the Maurice-Marie Janot Lecture and recently he has become a senior R&D advisor to Labs Servier.

Prior to joining NextPharma Prof Trevor Jones was Director General of the ABPI, he is also a member of the Board of Allergan Inc. and Chairman of the Merlin Bioscience stem cell company ReNeuron.

Bill Wedlake, CEO, NextPharma Technologies, commented on this prestigious appointment as follows:

“Prof Trevor Jones is a highly valued member of the NextPharma Board, since his appointment his knowledge and expertise has been of tremendous benefit to the development of our company. Trevor is widely respected in the industry for his dedication to scientific advancement within the field of pharmaceutical development.”

About NextPharma

NextPharma Technologies is a leading independent supplier in the fast growing biologics and pharma product development, clinical trials packaging, and manufacturing outsourcing sector. It has eight manufacturing facilities based in Germany, Belgium and France employing some 1,200 people and has a customer base which includes many of the worlds leading pharmaceutical companies.

-Ends-

For further information please contact:

Bill Wedlake

Chief Executive Officer

NextPharma Technologies Holding Limited

Tel +44 (0) 1483 479 121